CN110353263A - 一种抗肿瘤的甘薯和大豆异黄酮组合物及其应用 - Google Patents
一种抗肿瘤的甘薯和大豆异黄酮组合物及其应用 Download PDFInfo
- Publication number
- CN110353263A CN110353263A CN201810315180.0A CN201810315180A CN110353263A CN 110353263 A CN110353263 A CN 110353263A CN 201810315180 A CN201810315180 A CN 201810315180A CN 110353263 A CN110353263 A CN 110353263A
- Authority
- CN
- China
- Prior art keywords
- sweet potato
- composition
- isoflavones
- health care
- quality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000017020 Ipomoea batatas Species 0.000 title claims abstract description 105
- 235000002678 Ipomoea batatas Nutrition 0.000 title claims abstract description 105
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 235000008696 isoflavones Nutrition 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 150000002515 isoflavone derivatives Chemical class 0.000 title claims abstract description 43
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 27
- 230000036541 health Effects 0.000 claims abstract description 49
- 239000000843 powder Substances 0.000 claims abstract description 42
- 239000012452 mother liquor Substances 0.000 claims abstract description 32
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 25
- 229920001592 potato starch Polymers 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 230000001376 precipitating effect Effects 0.000 claims abstract description 10
- 239000007787 solid Substances 0.000 claims abstract description 8
- 244000068988 Glycine max Species 0.000 claims abstract description 4
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical group [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- 235000011090 malic acid Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 241000206575 Chondrus crispus Species 0.000 claims description 2
- 159000000013 aluminium salts Chemical class 0.000 claims description 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- 229960004106 citric acid Drugs 0.000 claims 1
- 235000012209 glucono delta-lactone Nutrition 0.000 claims 1
- 229960003681 gluconolactone Drugs 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 230000002265 prevention Effects 0.000 abstract description 9
- 239000004375 Dextrin Substances 0.000 abstract description 8
- 229920001353 Dextrin Polymers 0.000 abstract description 8
- 235000019425 dextrin Nutrition 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 4
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 abstract 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 abstract 1
- 235000013355 food flavoring agent Nutrition 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 6
- 235000020712 soy bean extract Nutrition 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001560086 Pachyrhizus Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012472 bioassay-guided isolation Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000009990 desizing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/105—Sweet potatoes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及保健食品及医药领域,具体涉及一种抗肿瘤的甘薯和大豆异黄酮的组合物及其应用。包括甘薯保健粉和大豆异黄酮,所述甘薯保健粉的制备方法为:在50~100℃下,向甘薯淀粉母液中加入质量占甘薯淀粉母液质量0.01~5%的沉淀剂后,分离、取固体物干燥和粉碎。所述的甘薯保健粉是从甘薯中提取的具有抗肿瘤作用的保健成分,大豆异黄酮是从大豆中提取的具有保健作用的异黄酮类成分,辅料为糊精等赋形剂和调味剂。本发明提供的复合甘薯颗粒保健食品,预防肿瘤效果显著,口感良好。
Description
技术领域
本发明涉及保健食品及医药领域,具体涉及一种抗肿瘤的甘薯和大豆异黄酮的组合物及其应用。
背景技术
肿瘤是严重威胁人类健康的恶性疾病,在我国,癌症已成为疾病死因之首,且发病率和死亡率还在攀升。寻找开发疗效确切、毒副作用小的预防和抗肿瘤产品一直是研发的热点。
甘薯是薯蓣科薯蓣属缠绕草质藤本,又称红薯、甜署、白薯、番薯、地瓜等,是我国的粮食作物之一,其种植面积及产量均居世界首位。据《本草纲目》记载,甘薯“味甘、平、无毒。主治补虚乏、益气力、健脾胃、强肾阴。功同薯蓣”。现代研究结果表明(王洪云等,中国食物与营养,2013,19(12):59-62)甘薯具有抗癌、提高免疫、降血脂、降血糖、抑制血栓形成、防治动脉硬化和心脏血管疾病等多种功效。甘薯蛋白有显著的抗肿瘤作用(Peng-Gao Li,etc。Anticancer effects of sweet potato protein on human colorectal cancercells。World J Gastroenterol,2013,19(21):3300-3308),最近的研究发现甘薯糖蛋白也具有抗肿瘤作用(Meimei Wang,etc。Bioassay-guided isolation of glycoprotein SPG-56from sweet potato Zhongshu-1and its anti-colon cancer activity in vitro andin vivo。Journal of Functional Foods.35,(2017),315-324)。利用甘薯的抗肿瘤保健成分开发具有预防肿瘤等保健作用的产品,前景广阔。但是,甘薯保健成分及其抗肿瘤保健作用在生活中并未得到充分开发利用。
大豆异黄酮是豆科植物的重要成分,抗肿瘤动物实验及体外实验均显示大豆异黄酮对乳腺癌、前列腺癌、结肠癌、肝癌、胃癌及白血病具有抑制肿瘤细胞增殖及抑制肿瘤生长作用;其抗肿瘤机制包括性激素样作用、抗氧化作用、诱导细胞程序性死亡及抑制酪氨酸激酶活性和抑制拓扑异构酸Ⅱ活性等。但是,单用大豆异黄酮,其抗肿瘤作用还有很大的不足。
发明内容
为解决上述问题本发明提供一种具有抗肿瘤作用的甘薯和大豆异黄酮的组合物,该组合物将一种从甘薯淀粉母液提取得甘薯保健粉与大豆异黄酮复配,利用其协同作用,显著提高其抗肿瘤作用。
一种具有抗肿瘤作用的甘薯和大豆异黄酮的组合物,其特征在于,包括甘薯保健粉和大豆异黄酮,所述甘薯保健粉的制备方法为:在50~100℃下,向甘薯淀粉母液中加入质量占甘薯淀粉母液质量0.01~5%的沉淀剂后,分离、取固体物干燥和粉碎。
进一步的,所述大豆异黄酮是指异黄酮含量为1~99%的大豆提取物。
进一步的,所述组合物还包括辅料,甘薯保健粉质量占组合物质量的1~90%、大豆异黄酮质量占组合物质量的1~90%,余量为辅料。
所述辅料可以是食品上可接受的/药用辅料,药用辅料是指赋形剂、矫味剂、崩解剂、助溶剂、黏合剂、润滑剂和缓释剂等,食品上可接受的辅料包括甜味剂、色素、香精、糊精和营养强化剂等。
进一步的,甘薯保健粉质量占组合物质量的20~50%、大豆异黄酮质量占组合物质量的20~50%,余量为辅料。
进一步的,所述沉淀过程的温度为60~90℃,所述沉淀剂的量为甘薯淀粉母液质量的0.05~1%,所述沉淀剂为钙盐、镁盐、铝盐、醋酸、苹果酸、柠檬酸、酒石酸、葡萄糖内酯、海藻酸钠、黄原胶和卡拉胶中的一种或多种。
进一步的,所述干燥是指干燥至固体物的含水量不超过10%,粉碎是指粉碎后的得到的甘薯保健粉的粒径小于20目。
进一步的,所述沉淀过程的沉淀温度为70~90℃,所述沉淀剂为硫酸钙、硫酸镁、酒石酸、苹果酸、柠檬酸和葡萄糖酸内酯的沉淀剂一种或多种。
进一步的,所述干燥是指干燥至固体物中含水量不超过5%,粉碎所得组合物的粒径小于100目。
上述具有抗肿瘤作用的甘薯和大豆异黄酮的组合物在制备治疗和/预防肿瘤的药物/保健品中的应用也属于本发明的保护范围。
本发明所述的甘薯淀粉母液是指除去了甘薯淀粉的母液,俗称黄浆或淀粉废水,其可以使甘薯淀粉生产中产生的废液;也可以是将甘薯与水一并粉碎,除去淀粉,收集得到的浆液。
本发明提供的具有抗肿瘤活性的甘薯和大豆异黄酮的组合物,由于甘薯保健粉和大豆异黄酮的协同作用,其具有显著的抗肿瘤作用和预防作用,预防作用远大于二者单用的效果。在给药浓度相同的情况下,二者单用时,小鼠的肿瘤发生率均为90%,肿瘤平均质量0.8~0.9g,二者联用时(本组合物),小鼠肿瘤的发生率降低至30%,肿瘤平均质量降低至0.25~0.49g。
具体实施方式
以下将结合实施例对本发明进行进一步的说明。
实施例1甘薯淀粉母液的制备
将100公斤甘薯洗净,粉碎过20目,磨细后的混合物转入滤孔为400目的喷淋洗涤离心机,边离心边用10L水喷淋,得到淀粉溶液和甘薯渣;将淀粉溶液离心去除淀粉,得到甘薯淀粉母液。
实施例2甘薯保健粉的制备
100℃下,向10L甘薯淀粉母液中加入重量为母液重量0.01%的硫酸钙,搅拌均匀,冷却到80℃,离心,60℃下真空干燥至含水量不超过10%,50目筛粉碎,得到甘薯保健粉。
实施例3甘薯保健粉的制备
50℃下,向10L甘薯淀粉母液中加入重量为母液重量1%的硫酸铝,搅拌均匀,冷却到20℃,离心,60℃下真空干燥至含水量不超过10%,50目筛粉碎得到甘薯保健粉。
实施例4甘薯保健粉的制备
70℃下,向10L甘薯淀粉母液中加入重量为母液重量0.1%的醋酸,搅拌均匀,冷却到20℃,离心,60℃下真空干燥至含水量不超过8%,100目筛粉碎得到甘薯保健粉。
实施例5甘薯保健粉的制备
90℃下,向10L甘薯淀粉母液中加入重量为母液重量0.05%的柠檬酸,搅拌均匀,冷却到30℃,离心,60℃下真空干燥至含水量不超过10%,100目筛粉碎得到甘薯保健粉。
实施例6甘薯保健粉的制备
80℃下,向10L甘薯淀粉母液中加入重量为母液重量0.5%的苹果酸,搅拌均匀,冷却到40℃,离心,60℃下真空干燥至含水量不超过8%,50目筛粉碎得到甘薯保健粉。
实施例7甘薯保健粉的制备
60℃下,向10L甘薯淀粉母液中加入重量为母液重量2%的葡萄糖酸内酯,搅拌均匀,冷却到25℃,离心,60℃下真空干燥至含水量不超过5%,100目筛粉碎得到甘薯保健粉。
实施例8甘薯保健粉的制备
60℃下,向10L甘薯淀粉母液中加入重量为母液重量2%的海藻酸钠,搅拌均匀,冷却到25℃,离心,60℃下真空干燥至含水量不超过9%,100目筛粉碎得到甘薯保健粉。
实施例9甘薯保健粉的制备
60℃下,向10L甘薯淀粉母液中加入重量为母液重量2%的葡萄糖酸内酯,搅拌均匀,冷却到25℃,离心,60℃下真空干燥至含水量不超过12%,100目筛粉碎得到甘薯保健粉。
实施例10甘薯保健粉的制备
60℃下,向10L甘薯淀粉母液中加入重量为母液重量2%的海藻酸钠,搅拌均匀,冷却到25℃,离心,60℃下真空干燥至含水量不超过15%,100目筛粉碎得到甘薯保健粉。
实施例11复合甘薯颗粒的制备
取甘薯保健粉90g、大豆异黄酮1g、糊精8.9g、甜蜜素0.1g,混合均匀,按照一般制粒工艺制粒,60℃下烘干,分装即可。大豆异黄酮为购买的食品级大豆提取物,异黄酮含量为99%。该产品具有较好的预防肿瘤效果。
实施例12组合物的制备
取甘薯保健粉1g、大豆异黄酮90g、糊精5g、蔗糖4g,混合均匀,按照一般制粒工艺制粒,60℃下烘干,装胶囊即可。大豆异黄酮为购买的食品级大豆提取物,异黄酮含量为1%。该产品具有较好的预防肿瘤效果。
实施例13组合物的制备
取甘薯保健粉20g、大豆异黄酮50g、糊精25g、白糖5g,混合均匀,按照一般制粒工艺制粒,60℃下烘干,分装即可。大豆异黄酮为购买的食品级大豆提取物,异黄酮含量为20%。该产品具有较好的预防肿瘤效果。
实施例14组合物的制备
取甘薯保健粉50g、大豆异黄酮20g、糊精25g、白糖5g,混合均匀,按照一般制粒工艺制粒,60℃下烘干,分装即可。大豆异黄酮为购买的食品级大豆提取物,异黄酮含量为80%。该产品具有较好的预防肿瘤效果。
实施例15组合物的制备
取甘薯保健粉45g、大豆异黄酮45g、糊精9g、甜蜜素1g,混合均匀,按照一般制粒工艺制粒,60℃下烘干,分装即可。大豆异黄酮为购买的食品级大豆提取物,异黄酮含量为50%。该产品具有较好的预防肿瘤效果。
对照实施例1甘薯全提取物的制备
将10L甘薯淀粉母液干燥,减压浓缩至固型物含量20%,喷雾干燥,得到甘薯全提取物保健粉。
对照实施例2甘薯全提取物为原料配制的“复核甘薯颗粒”制备
甘薯全提取物45g、大豆异黄酮45g、糊精9g、甜蜜素1g,混合均匀,按照一般制粒工艺制粒,60℃下烘干,分装即可。大豆异黄酮为购买的食品级大豆提取物,异黄酮含量为50%。
预防肿瘤效果试验
1.试验材料
甘薯保健粉,实施例2-10任一实施例制备的保健粉;
甘薯全提取物,对照实施例1制备;
大豆异黄酮:为购买的产品,异黄酮含量50%;
组合物,实施例11-15任一实施例制备(其中,所用的大豆异黄酮为异黄酮含量为50%的市售品);
对照组合物,对照实施例2制备;
MCF-7肿瘤细胞,选择生长对数期的MCF-7肿瘤细胞,用0.25%胰蛋白酶液消化1~2min,倒出消化液,加入PBS洗涤,反复吹打,将细胞悬液移至离心管中,1300rpm离心5min,弃上清,加入DMEM完全培养基,调整细胞浓度为1×108个/ml,0.4%台盼蓝检测活细胞>95%,备用。
2.试验动物
裸小鼠(nude mice):BALB/cnu,4周龄,100只,16-20g/只。
3.试验方法
将100只4周龄BALB/c nu裸鼠单笼饲养,屏障隔离系统平衡3~5天,无菌饲料和水充足。将裸鼠随机分为10组,每组10只,除阴性对照组外,各组裸鼠均接种肿瘤细胞(0.1ml/只),给予实验药物饲养,5g/(只*天),持续30天,30天后,处死老鼠,取下肿瘤块,称重,分析比较每组肿瘤组织平均重量,结果见表1。
4.试验结果
表1、抗肿瘤效果实验
试验组 | 肿瘤平均重量/g | 肿瘤发生率/% |
阴性对照组 | 0.00±0.00 | 0 |
阳性对照组 | 1.51±0.54 | 100 |
试验组1(甘薯保健粉,实施例6) | 0.88±0.55* | 90 |
试验组2(大豆异黄酮,50%含量) | 0.86±0.61* | 90 |
试验组3(组合物,对照实施例1) | 1.27±0.47 | 100 |
试验组4(组合物,实施例11) | 0.45±0.37**# | 60 |
试验组5(组合物,实施例12) | 0.39±0.86**# | 60 |
试验组6(组合物,实施例13) | 0.31±0.32**## | 40 |
试验组7(组合物,实施例15) | 0.28±0.25**## | 30 |
试验组8(对照组合物,对照实施例2) | 0.92±0.79 | 90 |
试验结果表明,与阳性对照组相比(*组),甘薯保健粉和大豆异黄酮均有较好的抗肿瘤效果(达到显著水平),而甘薯全提取物也有一定的抗肿瘤效果,但很差(未达显著水平);甘薯保健粉与大豆异黄酮复合后,尽管给药剂量相同,其抗肿瘤效果显著提升,达极显著水平,表明二者有明显的协同作用;随着配比的进一步优化,其抗肿瘤效果进一步提高;而大豆异黄酮与甘薯全提取物复核后,其抗肿瘤效果有所增加,但未达显著水平。
与大豆异黄酮和甘薯保健粉组相比(#组),复合甘薯颗粒保健食品抗肿瘤效果显著提升,达显著水平,表明二者有明显的协同作用;随着配比的进一步优化,其抗肿瘤效果进一步提高,达到极显著水平。
此外,从肿瘤发生率看,大豆异黄酮和甘薯保健粉均有预防肿瘤的作用,而甘薯全提取物却没有该作用;组合物预防肿瘤的效果进一步提高,表明组合物具有预防肿瘤的效果。
Claims (9)
1.一种具有抗肿瘤作用的甘薯和大豆异黄酮的组合物,其特征在于,包括甘薯保健粉和大豆异黄酮,所述甘薯保健粉的制备方法为:在50~100℃下,向甘薯淀粉母液中加入质量占甘薯淀粉母液质量0.01~5%的沉淀剂后,分离、取固体物干燥和粉碎。
2.如权利要求1所述的组合物,其特征在于,所述大豆异黄酮是指异黄酮含量为1~99%的大豆提取物。
3.如权利要求2所述的组合物,其特征在于,所述组合物还包括辅料,甘薯保健粉质量占组合物质量的1~90%、大豆异黄酮质量占组合物质量的1~90%,余量为辅料。
4.如权利要求3所述的组合物,其特征在于,甘薯保健粉质量占组合物质量的20~50%、大豆异黄酮质量占组合物质量的20~50%,余量为辅料。
5.如权利要求1所述的组合物,其特征在于,所述沉淀过程的温度为60~90℃,所述沉淀剂的量为甘薯淀粉母液质量的0.05~1%,所述沉淀剂为钙盐、镁盐、铝盐、醋酸、苹果酸、柠檬酸、酒石酸、葡萄糖内酯、海藻酸钠、黄原胶和卡拉胶中的一种或多种。
6.如权利要求5所述的组合物,其特征在于,所述干燥是指干燥至固体物的含水量不超过10%,粉碎是指粉碎后的得到的甘薯保健粉的粒径大于50目。
7.如权利要求5所述的组合物,其特征在于,所述沉淀过程的沉淀温度为70~90℃,所述沉淀剂为硫酸钙、硫酸镁、酒石酸、苹果酸、柠檬酸和葡萄糖酸内酯的沉淀剂一种或多种。
8.如权利要求7所述的组合物,其特征在于,所述干燥是指干燥至固体物中含水量不超过5%,粉碎所得组合物的粒径大于100目。
9.如权利要求1-8所述组合物在制备治疗和/预防肿瘤的药物/保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810315180.0A CN110353263B (zh) | 2018-04-10 | 2018-04-10 | 一种抗肿瘤的甘薯和大豆异黄酮组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810315180.0A CN110353263B (zh) | 2018-04-10 | 2018-04-10 | 一种抗肿瘤的甘薯和大豆异黄酮组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110353263A true CN110353263A (zh) | 2019-10-22 |
CN110353263B CN110353263B (zh) | 2022-10-14 |
Family
ID=68212901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810315180.0A Active CN110353263B (zh) | 2018-04-10 | 2018-04-10 | 一种抗肿瘤的甘薯和大豆异黄酮组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110353263B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070072641A (ko) * | 2006-01-02 | 2007-07-05 | 주식회사 두산 | 볶은 콩 분말을 이용한 약주 및 그 제조방법 |
CN105942507A (zh) * | 2016-05-23 | 2016-09-21 | 福建农林大学 | 一种具有防瘤抑瘤功能的全价营养组合物及其制备方法 |
CN106333193A (zh) * | 2016-08-19 | 2017-01-18 | 山东省食品发酵工业研究设计院 | 一种甘薯淀粉加工废水全资源化利用方法 |
CN107384703A (zh) * | 2017-08-07 | 2017-11-24 | 云南肠和健康科技股份有限公司 | 一种红薯酵素养生酒及其制备方法 |
CN107854590A (zh) * | 2016-09-22 | 2018-03-30 | 西南大学 | 一种甘薯皂苷提取物及其应用 |
-
2018
- 2018-04-10 CN CN201810315180.0A patent/CN110353263B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070072641A (ko) * | 2006-01-02 | 2007-07-05 | 주식회사 두산 | 볶은 콩 분말을 이용한 약주 및 그 제조방법 |
CN105942507A (zh) * | 2016-05-23 | 2016-09-21 | 福建农林大学 | 一种具有防瘤抑瘤功能的全价营养组合物及其制备方法 |
CN106333193A (zh) * | 2016-08-19 | 2017-01-18 | 山东省食品发酵工业研究设计院 | 一种甘薯淀粉加工废水全资源化利用方法 |
CN107854590A (zh) * | 2016-09-22 | 2018-03-30 | 西南大学 | 一种甘薯皂苷提取物及其应用 |
CN107384703A (zh) * | 2017-08-07 | 2017-11-24 | 云南肠和健康科技股份有限公司 | 一种红薯酵素养生酒及其制备方法 |
Non-Patent Citations (1)
Title |
---|
叶子等: "甘薯淀粉废水营养成分的提取及其免疫活性研究", 《现代农业科技》 * |
Also Published As
Publication number | Publication date |
---|---|
CN110353263B (zh) | 2022-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100510239B1 (ko) | 옥수수 수염과 식이섬유를 함유하는 조성물의 제조방법 | |
US11633444B2 (en) | Sporoderm-removed Ganoderma lucidum spore powder, granule and preparation method thereof | |
RU2475256C2 (ru) | Лекарственный травяной экстракт, обладающий эффектом против ожирения | |
KR20120003693A (ko) | 적포도 추출물, 녹차 추출물, 대두 추출물 및 l-카르니틴을 유효성분으로 함유하는 항비만 조성물 | |
CN107320487A (zh) | 一种甘氨酸亚铁补铁制剂及其制备方法 | |
KR102138348B1 (ko) | 뇌전증의 예방 또는 치료용 조성물 및 그 제조방법 | |
KR100854698B1 (ko) | 홍삼 식이섬유 추출방법 및 상기 방법에 의하여 추출된홍삼 식이섬유 | |
CN107613998A (zh) | 作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品 | |
KR20170082249A (ko) | 참옻나무 목심 추출물을 함유하는 항암치료 부작용에 따른 소화기능장애, 백혈구 감소증 및 골수부전증의 개선, 예방 또는 치료용 조성물 | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
CN103142916A (zh) | 一种预防和治疗老年性痴呆病的药物及其制备方法 | |
CN110353263A (zh) | 一种抗肿瘤的甘薯和大豆异黄酮组合物及其应用 | |
CN111789927A (zh) | 中药提取物及其制备方法 | |
KR101828167B1 (ko) | 아로니아 추출물을 함유하는 비만의 예방 또는 치료용 조성물 및 이의 제조방법 | |
KR101793145B1 (ko) | 가시박 추출물 또는 이의 분획물을 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 조성물 | |
CN111729056A (zh) | 抗癌的药物组合物及其制备方法 | |
JP4580447B2 (ja) | アガリクス含有組成物 | |
CN107125743A (zh) | 一种改善老年人心脑血管红树莓复合冲剂的配方 | |
KR100446061B1 (ko) | 유기용매흡착성 생약 미립구를 포함하는 숙취경감용 약학조성물 및 건강 보조식품 | |
KR102595767B1 (ko) | 밀몽화 추출물을 포함하는 악액질의 예방, 개선 또는 치료용 조성물 | |
CN108902814A (zh) | 白及护胃减肥产品及其应用 | |
CN106728019B (zh) | 一种治疗结直肠癌的中药组合物及其应用 | |
CN111388563B (zh) | 一种用于预防新生儿母乳性黄疸的组合物及其制备方法和应用 | |
JP2001097881A (ja) | マイタケ由来の発がん防止剤及び発がん防止用食品又は飼料 | |
KR101801130B1 (ko) | 복합생약 추출물을 유효성분으로 함유하는 여성 호르몬 조절이상 질환의 예방 및 개선을 위한 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |